Alexander Zukiwski, MD, CEO, Arno Therapeutics, Inc., discusses the efficacy of onapristone (ONA) in progesterone receptor (PR)-expressing tumors.
Alexander Zukiwski, MD
Advertisement
Articles by Alexander Zukiwski, MD
Advertisement
Latest Updated Articles
Efficacy of Onapristone in PR-Expressing TumorsPublished: July 14th 2015 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
